OCREVUS is dosed twice yearly, with no mandatory ongoing laboratory monitoring

Doses of OCREVUS (ocrelizumab) must be separated by at least 20 weeks.

Pretreatment evaluation

  • Hepatitis B virus screening should be performed in all patients before initiation of treatment with OCREVUS
  • Administer all immunizations according to immunization guidelines at least 4 weeks prior to initiation of OCREVUS for live or live-attenuated vaccines and, whenever possible, at least 2 weeks prior to initiation of OCREVUS for non-live vaccines

Preparation before every infusion

Infection assessment
  • Determine whether there is an active infection. In case of active infection, delay infusion of OCREVUS until infection resolves
Recommended premedication
  • Premedicate with 100 mg IV methylprednisolone (or equivalent) approximately 30 minutes before each infusion
  • Premedicate with an antihistamine (eg, diphenhydramine) approximately 30 to 60 minutes prior to each OCREVUS infusion
  • The addition of an antipyretic (eg, acetaminophen) may also be considered

Delayed or missed doses

  • If a planned infusion of OCREVUS is missed, administer OCREVUS as soon as possible; do not wait until the next scheduled dose
  • Reset the dose schedule to administer the sequential dose 6 months (24 weeks) after the missed dose is administered

Recommended dose, infusion rate, and infusion duration for RMS and PPMS

*Infusion may take longer if the infusion is interrupted or slowed.
Administer the first subsequent dose 6 months after infusion 1 of the initial dose.
The Infusion Center Locator is non-medication and non-disease specific, so it contains sites that may not infuse OCREVUS or that may not be covered by a particular patient's insurance provider.

Solutions of OCREVUS for intravenous infusion are prepared by dilution of the drug product into an infusion bag containing 0.9% sodium chloride injection, to a final drug concentration of approximately 1.2 mg/mL.

View the full Prescribing Information for complete Dosage and Administration.


PPMS=primary progressive multiple sclerosis; RMS=relapsing multiple sclerosis.

Infusion Center Locator

The National Infusion Center Association (NICA) maintains an Infusion Center Locator, which helps connect patients with sites of infusion care in their communities.